PET scans as a predictive marker of survival in advanced colorectal cancer.

BACKGROUND

The clinical utility of fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan in predicting the outcome of patients with metastatic colorectal cancer (mCRC) has not been well studied. We hypothesized that standardized uptake value (SUV) in FDG-PET scans after treatment predicts outcomes among patients with mCRC.

PATIENTS AND METHODS

We retrospectively reviewed mCRC patients who had FDG-PET scans before their treatment and measured their SUV on follow-up imaging at the Karmanos Cancer Institute. Primary end points of time to progression (TTP) and overall survival (OS) were compared in 2 groups: follow-up (posttreatment) SUV of 0 versus > 0.

RESULTS

The study population consisted of 44 patients (median age of 58.1 years). Forty (91%) of the patients were treated first-line, 34 (77%) received an oxaliplatin-based regimen, and 7 (16%) received an irinotecan-based regimen. Thirty-four (77%) patients received concurrent bevacizumab. Median pretreatment SUV was 9.2 (range, 1.7-46.3), and median posttreatment SUV (in n = 41) was 4.0 (range, 0-14). The median percent change in SUV was -68.5% (range, -9.2% to -100%). The median time interval between scans was 2.6 months. There was no statistically significant difference noted between metabolic responders and nonresponders with regard to TTP and OS. However, patients with a posttreatment SUV of 0 had significantly longer OS than those with posttreatment SUV of > 0 (median, 42 vs. 25.2 months, respectively), and slightly longer TTP (median, 8.2 vs. 6.9 months, respectively).

CONCLUSION

Systemic therapy significantly decreased SUV on follow-up PET scans in advanced colorectal cancer patients. Absence of FDG uptake on follow-up PET scans was associated with markedly longer OS and slightly longer TTP.